Parkinson's disease: new dopaminergic delivery but neuroprotection remains elusive

  • Tankosic, Tim MD

  • Dr Tankosic is a freelance science writer.

Scrip Drug Market Developments 19(4):p 21-26, April 2008.
Current late-stage clinical drug development for Parkinson's disease (PD) includes new formulations of approved drugs and promising drugs with new mechanisms of action. Most of these are in development as adjuncts to levodopa-carbidopa therapy and several of them could be approved during the next three to five years. The first approval for a disease modifying (neuroprotective) agent could be granted by 2010, depending on the results of Teva/Lundbeck's rasagiline trial. Phase II studies with cell and gene therapies show promise for disease modification but these products will not have a clinical market impact during the next five years.
Copyright © 2008 Drug & Market Development